Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial (original) (raw)

Abstract

Intraperitoneal treatment with interferon-γ (IFN-γ) has been shown to achieve surgically documented responses in the second-line therapy of ovarian cancer. To assess its efficacy in the first-line therapy, we conducted a randomized controlled trial with 148 patients who had undergone primary surgery for FIGO stage Ic–IIIc ovarian cancer. In the control arm women received 100 mg m−2cisplatin and 600 mg m−2cyclophosphamide, the experimental arm included the above regimen with IFN-γ 0.1 mg subcutaneously on days 1, 3, 5, 15, 17 and 19 of each 28-day cycle. Progression-free survival at 3 years was improved from 38% in controls to 51% in the treatment group corresponding to median times to progression of 17 and 48 months (P = 0.031, relative risk of progression 0.48, confidence interval 0.28–0.82). Three-year overall survival was 58% and 74% accordingly (n.s., median not yet reached). Complete clinical responses were observed in 68% with IFN-γ versus 56% in controls (n.s.). Toxicity was comparable in both groups except for a mild flu-like syndrome, experienced by most patients after administration of IFN-γ. Thus, with acceptable toxicity, the inclusion of IFN-γ in the first-line chemotherapy of ovarian cancer yielded a benefit in prolonging progression-free survival. © 2000 Cancer Research Campaign

Keywords: randomized phase III trial, multicentre study, ovarian cancer, interferon-type II

Full Text

The Full Text of this article is available as a PDF (79.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allavena P., Peccatori F., Maggioni D., Erroi A., Sironi M., Colombo N., Lissoni A., Galazka A., Meiers W., Mangioni C. Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells. Cancer Res. 1990 Nov 15;50(22):7318–7323. [PubMed] [Google Scholar]
  2. Aulitzky W., Gastl G., Aulitzky W. E., Nachbaur K., Lanske B., Kemmler G., Flener R., Frick J., Huber C. Interferon-gamma for the treatment of metastatic renal cancer: dose-dependent stimulation and downregulation of beta-2 microglobulin and neopterin responses. Immunobiology. 1987 Dec;176(1-2):85–95. doi: 10.1016/s0171-2985(87)80102-x. [DOI] [PubMed] [Google Scholar]
  3. Berek J. S., Hacker N. F., Lichtenstein A., Jung T., Spina C., Knox R. M., Brady J., Greene T., Ettinger L. M., Lagasse L. D. Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Cancer Res. 1985 Sep;45(9):4447–4453. [PubMed] [Google Scholar]
  4. Billiau A. Interferon-gamma: biology and role in pathogenesis. Adv Immunol. 1996;62:61–130. doi: 10.1016/s0065-2776(08)60428-9. [DOI] [PubMed] [Google Scholar]
  5. Boehm U., Klamp T., Groot M., Howard J. C. Cellular responses to interferon-gamma. Annu Rev Immunol. 1997;15:749–795. doi: 10.1146/annurev.immunol.15.1.749. [DOI] [PubMed] [Google Scholar]
  6. Colombo N., Peccatori F., Paganin C., Bini S., Brandely M., Mangioni C., Mantovani A., Allavena P. Anti-tumor and immunomodulatory activity of intraperitoneal IFN-gamma in ovarian carcinoma patients with minimal residual tumor after chemotherapy. Int J Cancer. 1992 Apr 22;51(1):42–46. doi: 10.1002/ijc.2910510109. [DOI] [PubMed] [Google Scholar]
  7. D'Acquisto R., Markman M., Hakes T., Rubin S., Hoskins W., Lewis J. L., Jr A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma. J Clin Oncol. 1988 Apr;6(4):689–695. doi: 10.1200/JCO.1988.6.4.689. [DOI] [PubMed] [Google Scholar]
  8. Dighe A. S., Richards E., Old L. J., Schreiber R. D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity. 1994 Sep;1(6):447–456. doi: 10.1016/1074-7613(94)90087-6. [DOI] [PubMed] [Google Scholar]
  9. Hancock M. C., Langton B. C., Chan T., Toy P., Monahan J. J., Mischak R. P., Shawver L. K. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res. 1991 Sep 1;51(17):4575–4580. [PubMed] [Google Scholar]
  10. Kaplan D. H., Shankaran V., Dighe A. S., Stockert E., Aguet M., Old L. J., Schreiber R. D. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556–7561. doi: 10.1073/pnas.95.13.7556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kleinerman E. S., Kurzrock R., Wyatt D., Quesada J. R., Gutterman J. U., Fidler I. J. Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant gamma-interferon. Cancer Res. 1986 Oct;46(10):5401–5405. [PubMed] [Google Scholar]
  12. Malik S. T., Knowles R. G., East N., Lando D., Stamp G., Balkwill F. R. Antitumor activity of gamma-interferon in ascitic and solid tumor models of human ovarian cancer. Cancer Res. 1991 Dec 15;51(24):6643–6649. [PubMed] [Google Scholar]
  13. Maluish A. E., Urba W. J., Longo D. L., Overton W. R., Coggin D., Crisp E. R., Williams R., Sherwin S. A., Gordon K., Steis R. G. The determination of an immunologically active dose of interferon-gamma in patients with melanoma. J Clin Oncol. 1988 Mar;6(3):434–445. doi: 10.1200/JCO.1988.6.3.434. [DOI] [PubMed] [Google Scholar]
  14. Marth C., Fuith L. C., Böck G., Daxenbichler G., Dapunt O. Modulation of ovarian carcinoma tumor marker CA-125 by gamma-interferon. Cancer Res. 1989 Dec 1;49(23):6538–6542. [PubMed] [Google Scholar]
  15. Marth C., Müller-Holzner E., Greiter E., Cronauer M. V., Zeimet A. G., Doppler W., Eibl B., Hynes N. E., Daxenbichler G. Gamma-interferon reduces expression of the protooncogene c-erbB-2 in human ovarian carcinoma cells. Cancer Res. 1990 Nov 1;50(21):7037–7041. [PubMed] [Google Scholar]
  16. Marth C., Widschwendter M., Kaern J., Jørgensen N. P., Windbichler G., Zeimet A. G., Tropé C., Daxenbichler G. Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells. Br J Cancer. 1997;76(10):1328–1332. doi: 10.1038/bjc.1997.556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Marth C., Zeimet A. G., Herold M., Brumm C., Windbichler G., Müller-Holzner E., Offner F., Feichtinger H., Zwierzina H., Daxenbichler G. Different effects of interferons, interleukin-1beta and tumor necrosis factor-alpha in normal (OSE) and malignant human ovarian epithelial cells. Int J Cancer. 1996 Sep 17;67(6):826–830. doi: 10.1002/(SICI)1097-0215(19960917)67:6<826::AID-IJC12>3.0.CO;2-#. [DOI] [PubMed] [Google Scholar]
  18. McGuire W. P., Hoskins W. J., Brady M. F., Kucera P. R., Partridge E. E., Look K. Y., Clarke-Pearson D. L., Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996 Jan 4;334(1):1–6. doi: 10.1056/NEJM199601043340101. [DOI] [PubMed] [Google Scholar]
  19. Männel D. N., Falk W. Interferon-gamma is required in activation of macrophages for tumor cytotoxicity. Cell Immunol. 1983 Jul 15;79(2):396–402. doi: 10.1016/0008-8749(83)90082-5. [DOI] [PubMed] [Google Scholar]
  20. Nehme A., Julia A. M., Jozan S., Chevreau C., Bugat R., Canal P. Modulation of cisplatin cytotoxicity by human recombinant interferon-gamma in human ovarian cancer cell lines. Eur J Cancer. 1994;30A(4):520–525. doi: 10.1016/0959-8049(94)90430-8. [DOI] [PubMed] [Google Scholar]
  21. Pujade-Lauraine E., Guastalla J. P., Colombo N., Devillier P., François E., Fumoleau P., Monnier A., Nooy M., Mignot L., Bugat R. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol. 1996 Feb;14(2):343–350. doi: 10.1200/JCO.1996.14.2.343. [DOI] [PubMed] [Google Scholar]
  22. Saito T., Berens M. E., Welander C. E. Direct and indirect effects of human recombinant gamma-interferon on tumor cells in a clonogenic assay. Cancer Res. 1986 Mar;46(3):1142–1147. [PubMed] [Google Scholar]
  23. Weisenthal L. M., Dill P. L., Pearson F. C. Effect of prior cancer chemotherapy on human tumor-specific cytotoxicity in vitro in response to immunopotentiating biologic response modifiers. J Natl Cancer Inst. 1991 Jan 2;83(1):37–42. doi: 10.1093/jnci/83.1.37. [DOI] [PubMed] [Google Scholar]
  24. Welander C. E., Homesley H. D., Reich S. D., Levin E. A. A phase II study of the efficacy of recombinant interferon gamma in relapsing ovarian adenocarcinoma. Am J Clin Oncol. 1988 Aug;11(4):465–469. doi: 10.1097/00000421-198808000-00011. [DOI] [PubMed] [Google Scholar]